Growth hormone biology is organized as an axis: a chain of signals running from the hypothalamus to the pituitary to peripheral tissue, with feedback loops that keep the whole system in range. Tesamorelin shows up in that literature as a tool for one specific link in the chain, the receptor for growth hormone-releasing hormone (GHRH). This overview covers the axis, what makes tesamorelin structurally distinct from the native hormone, and what characterization matters when working with it in the lab.
Cerberus Research Labs supplies compounds strictly for laboratory research use. Nothing here is dosing guidance, medical advice, or a therapeutic claim, and no compound discussed is offered for human or veterinary use.
The GH axis in one page
Three signals set the rhythm of the axis:
- GHRH is released from the hypothalamus and acts on its receptor (GHRHR) on pituitary somatotroph cells. GHRHR is a G protein-coupled receptor that signals largely through Gs and cyclic AMP, and GHRH signaling supports both growth hormone synthesis and its release.
- Somatostatin, also hypothalamic, acts as the counterweight. It restrains GH release, and the interplay between GHRH and somatostatin tone is what gives GH its characteristic pulsatile secretion pattern rather than a steady level.
- Ghrelin, acting through a distinct receptor (GHSR), is a third input that amplifies GH release and is the target of the growth hormone secretagogue class of research compounds.
Downstream, GH acts on peripheral tissue, notably the liver, to drive production of insulin-like growth factor 1 (IGF-1), which in turn feeds back on the hypothalamus and pituitary. Studying any one link means being careful about the others, because the loops interact.
What tesamorelin is, structurally
Native human GHRH is a 44-residue peptide. Tesamorelin is built on that full-length sequence, with one engineered change: a trans-3-hexenoyl group attached to the N-terminal tyrosine. The reason this matters is enzymatic. Native GHRH is rapidly cleaved at its N-terminus by dipeptidyl peptidase IV (DPP-IV), which limits how long it persists in biological preparations. The hexenoyl cap is designed to hinder that cleavage, giving a GHRH-receptor ligand that is more stable than the native peptide in experimental settings.
This is a clean example of a broader design principle: a small, targeted modification at a known cleavage site can alter stability without redesigning the whole molecule. It also means tesamorelin retains the full-length sequence, which distinguishes it from the shortened GHRH analogs below.
How it relates to other compounds in the literature
- CJC-1295 (without DAC), sometimes called modified GRF(1-29), is a truncated analog containing the first 29 residues of GHRH with several amino acid substitutions intended to improve stability. The 1-29 fragment is generally described as the minimal sequence that retains full biological activity at the receptor. The version with DAC adds a drug affinity complex moiety designed to bind serum albumin, a different strategy for extending persistence.
- Growth hormone secretagogues such as ipamorelin act through the ghrelin receptor rather than GHRHR. Because they engage a different receptor on the same cell type, GHRH analogs and secretagogues are frequently compared or combined in mechanistic work on the axis.
- AOD-9604 is something different again: a modified fragment of the C-terminal region of GH itself, not a releasing factor. It belongs in the same conversation only because it comes up in GH-related searches.
The practical lesson for experimental design is to be explicit about which receptor and which step in the axis a given compound engages. Conflating a GHRH analog with a ghrelin-receptor agonist or a GH fragment produces uninterpretable results.
Experimental considerations
- Read-outs. Receptor-level work typically measures cAMP accumulation in cells expressing GHRHR. Pituitary-cell and tissue preparations measure GH release directly, and any such system needs controls for the somatostatin and feedback components noted above.
- Pulsatility. Because the axis is naturally pulsatile, the timing of sampling relative to stimulation can change what an experiment appears to show. Report sampling schedules explicitly.
- Identity and purity. A 44-residue peptide with an N-terminal modification has more places to go wrong than a short peptide. Confirm identity by mass and purity by HPLC against the lot-specific certificate of analysis; see the COA library and the documentation hub.
- Handling. Lyophilized peptide should be reconstituted with aseptic technique in a solvent suited to the assay, and stored according to the lot documentation. The reconstitution calculator helps with concentration arithmetic for stock solutions.
A note on regulatory context
Tesamorelin also has a regulatory history as a pharmaceutical substance. That history is separate from research-grade material supplied for laboratory use, and findings from clinical settings do not transfer to research compounds. Cerberus Research Labs makes no representation connecting the two.
Research use only. Not for human use. Not for veterinary use. Nothing on this page is medical advice, and no statement here should be read as a claim of safety, efficacy or suitability for any purpose outside laboratory research.
Where to go next
Browse the full research catalog, or see the product pages for tesamorelin and CJC-1295 (without DAC). Researchers working on adjacent metabolic signaling may also be interested in our overview of the GLP-1 research landscape.